TORM plc (TRMD) Stock Price Today
Key Stats
- $3.97BMarket Cap
- 1,173,047Volume
- IndustrialsSector
- $40.0052W High
- $19.3952W Low
- 23 DaysTypical Hold Time
- $4.67BEnterprise Value
- 11.64%Div Yield
- 83% Sell | 17% BuyTrading Activity
Track TORM plc (TRMD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TORM plc has traded between a low of $19.39 and a high of $40, highlighting its annual price range. Buy and sell TORM plc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Most Recent News
One sizable IPO, one direct listing, and one SPAC debuted; Oura delays multibillion-dollar IPO.
This week saw the debut of one sizable IPO, one direct listing, and one SPAC, alongside initial filings from three small IPOs, one direct listing, and six SPACs. Notably, Oura postponed its planned multibillion-dollar IPO, marking a significant devel...

Municipal bonds and high-yield muni-bond funds sharply sold off, raising risks and tax concerns.
Municipal bonds experienced a significant selloff over the past month, with high-yield municipal bond closed-end funds (CEFs) yielding over 8% dropping even more sharply. The article highlights data on five top big-yield muni-bond CEFs, focusing part...

Arrowhead's plozasiran shows strong results to challenge Ionis in severe hypertriglyceridemia market
Arrowhead Pharmaceuticals is set to compete with Ionis in treating severe hypertriglyceridemia (sHTG) using plozasiran, which benefits from a $215 million priority review voucher enabling a faster market launch. Phase III trials SHASTA-3 and SHASTA-4...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.